TRXC - Ready to jump in to the double digit's area TRXC robot surgery company, with unique laparoscopy technology called Senhance. You can see more on February 23. on a virtual conference. finance.yahoo.com
PT1: 6.5$ done
TOP: 6.95$
Between R1 (4.74) - MA20 (4.14) Moderated BUY, under 4.14 (blue arrow) Strong BUY and they also have some good news today.
finance.yahoo.com
PT2: 10.10$ /R4 - blue arrow/
Surgery
NSPR EMA and Volume rockingThe market atm is pretty boring. Bitcoin is doing nothing, stocks trading on news, Tesla mooning on earnings epectations with possibility of NASDAQ listing, cruise lines crap, and tech stocks booming. Now I been watching NSPR a little trying to find a good time to buy. NSPR is a medical stock that helps certain surgeries possible, yet its downfall is its not sold in the USA and it might be awhile till it is.
TA
-looking at the hourly and even the daily you can see its at its highest volume since June 02 the dump from .81 to now and has been mainting this high volume.
-hourly emas look to be cloing in a bullish move, yet on the daily it does get rejected, so entering the trade on emas targets range are .55-.7
-MACD is uptrending up on the daily and hourly
-RSI is overbought on the hourly, yet neutral on the daily.
-Earning are coming up and the last two earnings don't show much. Last one sideways and the other one it dumped, but pumped higher later.
I personally took a gamble and bought 3k shares, yet would keep this one on your radar just cause the volume at the moment is unlike anything it has done in the past.
Hi-Tech Medical+Robotics Play w/ $10 Stable, Transition RangeWith brand recognition and consistent sales in place, Mazor has stated that 2018 will be a transition year for them, not growth. Therefore, expect the company to aim for stability as it continues to spread its products. Per the last call: "2018 is expected to be a year of transition and our performance is expected to be driven primarily by increased revenues from the expanding installed base. Long-term, we would anticipate the installed base to expand considerably during the length of the global distribution agreement. Over the next five years, the largest result is a cumulative purchase of hundreds of Mazor X systems, which are expected to significantly accelerate procedure volume and growth."
Overall trend lines have been followed from 2017 into 2018 in a balanced manner. Some weakness definitely showed up after such a quick run-up into the -now- low part of this year's fib chart. A good period of accumulation presented itself before another push higher in January gave it momentum (along with everything else in the market). February hit, but the stock did not tumble horribly. It had one more push higher that went way beyond what anyone, anywhere was expecting. Forums were happily confused. As such, a LOT of profit taking took place and rightfully so after all the volatility that had been in play. Regardless, the company's fundamentals have not changed and the stock is now back to its previous, stable 2018 levels.
This is an excellent range to start a small position, as I expect the stock to continue trading back up close to $70 again with positive market momentum. Anything around the $56 level, where the stock has successfully bounced off of, is great for accumulation. A great company with an excellent product, vision and fundamentals makes holding this for stability within its range (and with opportunities for breakouts with ANY good news) a great pick for 2018. Technical trading within its $10 range ($58-68) is great for those who can time the market.
--Additional Backstory--
Mazor is a hi-tech, medical robotics company that specializes in creating systems for assistance during spinal surgery. Everyone knows that surgery is an expensive process and back surgery is extremely costly, difficult and more common than we'd care to imagine. The two systems that Mazor has developed and begun selling (in conjunction with Medtronic) are state of the art and well known within their field. While 2017 was quiet at first, the company began to grow in spurts with a huge push, in part from Medtronic, near the end of the year.